-+ 0.00%
-+ 0.00%
-+ 0.00%

BMO Capital Initiates Coverage On LB Pharmaceuticals with Outperform Rating, Announces Price Target of $46

Benzinga·07/21/2026 09:34:03
Listen to the news
BMO Capital analyst Malcolm Hoffman initiates coverage on LB Pharmaceuticals (NASDAQ:LBRX) with a Outperform rating and announces Price Target of $46.